Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Bernardo, Miquel
Vieta, Eduard
Saiz Ruiz, Jerónimo
Rico-Villademoros, Fernando
Álamo, Cecilio
and
Bobes, Julio
2011.
Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica.
Revista de Psiquiatría y Salud Mental,
Vol. 4,
Issue. 3,
p.
150.
De Hert, M.
Vancampfort, D.
Correll, C. U.
Mercken, V.
Peuskens, J.
Sweers, K.
van Winkel, R.
and
Mitchell, A. J.
2011.
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.
British Journal of Psychiatry,
Vol. 199,
Issue. 2,
p.
99.
Maayan, Lawrence
and
Correll, Christoph U.
2011.
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents.
Journal of Child and Adolescent Psychopharmacology,
Vol. 21,
Issue. 6,
p.
517.
Bernardo, Miquel
Vieta, Eduard
Saiz Ruiz, Jerónimo
Rico-Villademoros, Fernando
Álamo, Cecilio
and
Bobes, Julio
2011.
Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry.
Revista de Psiquiatría y Salud Mental (English Edition),
Vol. 4,
Issue. 3,
p.
150.
Pompili, Maurizio
Serafini, Gianluca
Innamorati, Marco
Ambrosi, Elisa
Telesforo, Ludovica
Venturini, Paola
Giordano, Gloria
Battuello, Michele
Lester, David
and
Girardi, Paolo
2011.
Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?.
Expert Review of Neurotherapeutics,
Vol. 11,
Issue. 7,
p.
989.
De Hert, Marc
Yu, Weiping
Detraux, Johan
Sweers, Kim
van Winkel, Ruud
and
Correll, Christoph U.
2012.
Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder.
CNS Drugs,
Vol. 26,
Issue. 9,
p.
733.
Morrato, Elaine H
2012.
An update on lipid profile screening in second-generation antipsychotic users in the USA.
Clinical Lipidology,
Vol. 7,
Issue. 5,
p.
509.
Hasnain, Mehrul
Vieweg, W. Victor R.
and
Hollett, Bruce
2012.
Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians.
Postgraduate Medicine,
Vol. 124,
Issue. 4,
p.
154.
Weston-Green, Katrina
Huang, Xu-Feng
Deng, Chao
and
Chang, Alice Y. W.
2012.
Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain.
PLoS ONE,
Vol. 7,
Issue. 3,
p.
e33548.
Abrahamian, Heidemarie
Kautzky-Willer, Alexandra
Rießland-Seifert, Angelika
Fasching, Peter
Ebenbichler, Christoph
Hofmann, Peter
and
Toplak, Hermann
2012.
Positionspapier: Psychische Erkrankungen und Diabetes mellitus.
Wiener klinische Wochenschrift,
Vol. 124,
Issue. S2,
p.
107.
Garcia, Georgina
Logan, Grace E.
and
Gonzalez-Heydrich, Joseph
2012.
Management of Psychotropic Medication Side Effects in Children and Adolescents.
Child and Adolescent Psychiatric Clinics of North America,
Vol. 21,
Issue. 4,
p.
713.
Harrison, Joyce Nolan
Cluxton-Keller, Fallon
and
Gross, Deborah
2012.
Antipsychotic Medication Prescribing Trends in Children and Adolescents.
Journal of Pediatric Health Care,
Vol. 26,
Issue. 2,
p.
139.
Moteshafi, Hoda
Zhornitsky, Simon
Brunelle, Sarah
and
Stip, Emmanuel
2012.
Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders.
Drug Safety,
Vol. 35,
Issue. 10,
p.
819.
Matone, Meredith
Localio, Russell
Huang, Yuan‐Shung
dosReis, Susan
Feudtner, Chris
and
Rubin, David
2012.
The Relationship between Mental Health Diagnosis and Treatment with Second‐Generation Antipsychotics over Time: A National Study of U.S. Medicaid‐Enrolled Children.
Health Services Research,
Vol. 47,
Issue. 5,
p.
1836.
Kölch, Michael G.
Plener, Paul L.
and
Fegert, Jörg M.
2012.
Handbuch der Psychopharmakotherapie.
p.
1185.
Goldbeck, Lutz
Plener, Paul L.
Resch, Franz
and
Fegert, Jörg M.
2012.
Psychiatrie und Psychotherapie des Kindes- und Jugendalters.
p.
177.
Moteshafi, Hoda
and
Stip, Emmanuel
2012.
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Expert Opinion on Drug Safety,
Vol. 11,
Issue. 5,
p.
713.
Heal, David J.
Gosden, Jane
Jackson, Helen C.
Cheetham, Sharon C.
and
Smith, Sharon L.
2012.
Current Antipsychotics.
Vol. 212,
Issue. ,
p.
135.
De Hert, Marc
Detraux, Johan
van Winkel, Ruud
Yu, Weiping
and
Correll, Christoph U.
2012.
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
Nature Reviews Endocrinology,
Vol. 8,
Issue. 2,
p.
114.
Constantine, Robert
Bengtson, Michael A.
Murphy, Tanya
McPherson, Marie
Andel, Ross
Jones, Mary Elizabeth
and
Donaldson-Guenther, Christina
2012.
Impact of the Florida Medicaid Prior-Authorization Program on Use of Antipsychotics by Children Under Age Six.
Psychiatric Services,
Vol. 63,
Issue. 12,
p.
1257.
Comments
No Comments have been published for this article.